Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Cellobiose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.58 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.58 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | AMY2A | P04746 | 3/20 | 0.52 |
| ▸ | TYR | P14679 | 2/20 | 0.48 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GJA1 | P17302 | 1/20 | 0.47 |
| ▸ | GJB2 | P29033 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | IGF2R | P11717 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cellobiose SCHEMBL5701237 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL18229206 | 0.97 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Maltotriose SCHEMBL28275648 | 0.97 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Maltotriose SCHEMBL24202675 | 0.97 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Maltotriose SCHEMBL23467170 | 0.97 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL25382543 | 0.97 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL24662526 | 0.97 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL21114355 | 0.97 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL21511124 | 0.97 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Maltotriose SCHEMBL20553487 | 0.97 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682484-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-26 | — | — | EP | claimed |
| WO-2005042465-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-05-12 | — | — | WO | claimed |
| US-20040192688-A1 | Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2004-09-30 | — | — | US | claimed |
| CN-102670541-A | Hydrochloride sinomenine composition and preparation method of hydrochloride sinomenine composition | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD | 2012-09-19 | — | — | CN | disclosed |
| US-7109326-B2 | Halo-alkoxycarbonyl prodrugs | GENENTECH, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-0975608-B1 | HALO-ALKOXYCARBONYL PRODRUGS | GENENTECH INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040220401-A1 | Novel halo-alkoxycarbonyl prodrugs | GENENTECH, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20010020019-A1 | NOVEL HALO-ALKOXYCARBONYL PRODRUGS | GENENTECH, INC. | 2001-09-06 | — | — | US | disclosed |
| EP-0975608-A2 | HALO-ALKOXYCARBONYL PRODRUGS | Genentech, Inc. (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046576-A2 | HALO-ALKOXYCARBONYL PRODRUGS | GENENTECH, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220401-A1 | Novel halo-alkoxycarbonyl prodrugs | PNP, PAICS, PHOSPHO1 | LGALS8 1895/4885LGALS3 1816/4885LGALS4 2225/4885 |
| US-20040192688-A1 | Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | APOB, LIPC, FABP3 | LGALS8 842/4885LGALS3 705/4885LGALS4 1187/4885 |
| US-20010020019-A1 | NOVEL HALO-ALKOXYCARBONYL PRODRUGS | PNP, PAICS, PHOSPHO1 | LGALS8 1895/4885LGALS3 1816/4885LGALS4 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.